X-Chem and Sironax have agreed a research partnership, in which X-Chem will use its DEL platform to support Sironax’s drug discovery pipeline.
Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.
“We appreciate being a preferred partner to support drug discovery projects across the Sironax portfolio,” said X-Chem CEO Matt Clark. “The combination of Sironax’s deep scientific knowledge and our leading DEL platform will help drive the discovery of new therapeutics that will help patients.”
X-Chem provides services to pharmaceutical and biotech companies for screening, hit validation and lead optimisation. Its DEL platform is designed to discover novel small molecule leads against challenging, high-value therapeutic targets.
Sironax is a clinical-stage biotechnology company focused on age-related degenerative diseases. The company’s pipeline targets key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation.